A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma
Part of paid clinical trials in Miami, Florida.
- Sponsor
- Jonathan Friedberg
- Study ID
- NCT03078855
- Phase
- PHASE3
- Status
- Completed
Conditions
- Follicular Lymphoma
- Marginal Zone Lymphoma
- Mucosal-Associated Lymphoid Tissue Lymphoma
- Small Lymphocytic Lymphoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Vitamin D — DIETARY_SUPPLEMENTvitamin D3 2,000 IU daily
- Rituximab — BIOLOGICALAdministered weekly x 4
- Placebo — OTHERmethylcellulose
Study Details
Despite strong evidence suggesting that vitamin D deficiency is associated with undesirable outcomes in patients with numerous cancers, there has never been a thorough study of vitamin D treatment in subjects undergoing treatment for cancer. The purpose of this study is to evaluate whether modification of vitamin D levels in the blood, through supplementation, can improve outcomes.
Key Dates
- Start date
- Sep 7, 2017
- Status verified
- Aug 2024
- Primary completion
- Jul 21, 2023
- Completion
- Jul 2, 2024
Study Design
- Enrollment
- 211 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: Vitamin D plus rituximabRituximab was administered weekly x 4 (intravenous 375 mg/m\^2 or subcutaneous equivalent) per institutional standards and vitamin D3, 2000 IU orally once daily. Participants took vitamin D3 until lack of response at week 13, disease progression, or initiation of a new treatment.
- Placebo Comparator: Placebo plus rituximabRituximab was administered weekly x 4 (intravenous 375 mg/m\^2 or subcutaneous equivalent) per institutional standards and placebo orally once daily. Participants took placebo until lack of response at week 13, disease progression, or initiation of a new treatment.
Primary Outcome Measure
Event Free Survival [ Time Frame: 3 years ]
Locations (7)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Miami | Miami | Florida | 33136 | - |
| Emory University, Winship Cancer Institute | Atlanta | Georgia | 30322 | - |
| University of Iowa | Iowa City | Iowa | 52242 | - |
| Washington University | St Louis | Missouri | 63130 | - |
| Weill Cornell Medical College | New York | New York | 10021 | - |
| James P. Wilmot Cancer Institute at University of Rochester Medical Center | Rochester | New York | 14642 | - |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | - |
Find similar trials in Miami, FL
By research site
Related Studies
- A Long-term Extension Study of PCI-32765 (Ibrutinib)PHASE3 · Recruiting · Janssen Research & Development, LLC · Duarte, California
- Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular LymphomaPHASE2 · Not Yet Recruiting · XEME Biopharma Inc. · Newnan, Georgia
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Evaluation of Human Immune Responses Vaccination in Patients With LymphomaRecruiting · Emory University · Atlanta, Georgia